Skip to main content

Table 1 Patient characteristics and PET parameters

From: Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer

Patient no.

Age (years)

Body weight (kg)

PSA (ng/l)

Activity (MBq)

Time to image acquisition (min)

PET-scanner

1

53

85

4.10

   

68Ga

   

177

61

Siemens Biograph 16

18F

   

350

175

Siemens Biograph 16

2

86

74

2.10

   

68Ga

   

139

109

Siemens Biograph 16

18F

   

347

170

Siemens Biograph 16

3

74

100

4.70

   

68Ga

   

138

122

Siemens Biograph 16

18F

   

364

93

Siemens Biograph 16

4

82

91

50.00

   

68Ga

   

139

65

Siemens Biograph 16

18F

   

382

112

Siemens Biograph 16

5

68

90

n. a

   

68Ga

   

104

49

Siemens Biograph 16

18F

   

411

126

Siemens Biograph 16

6

68

94

1.30

   

68Ga

   

139

129

Siemens Biograph 16

18F

   

349

128

Siemens Biograph 16

7

68

88

1.20

   

68Ga

   

110

74

Siemens Biograph mCT 128 Edge

18F

   

240

123

Siemens Biograph mCT 128 Edge

8

60

124

2.04

   

68Ga

   

95

49

Siemens Biograph mCT 128 Edge

18F

   

280

94

Siemens Biograph mCT 128 Edge

9

74

76

3.87

   

68Ga

   

64

57

Siemens Biograph mCT 128 Edge

18F

   

360

107

Siemens Biograph mCT 128 Edge

10

54

62

10.00

   

68Ga

   

187

64

Siemens Biograph mCT 128 Edge

18F

   

297

117

Siemens Biograph mCT 128 Edge

11

76

75

1.48

   

68Ga

   

160

67

Siemens Biograph mCT 128 Edge

18F

   

363

49

Siemens Biograph mCT 128 Edge

  1. PET positron emission tomography, PSA prostate-specific antigen in blood test, 68Ga [68Ga]Ga-PSMA-11, 18F [18F]F-DCFPyL, n. a. not available